ProBioGen, Boehringer Ingelheim deal

Boehringer received a non-exclusive license to use ProBioGen's GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) activity of antibodies. Boehringer said its contract manufa...